Search

Your search keyword '"Lampiris H"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Lampiris H" Remove constraint Author: "Lampiris H" Language english Remove constraint Language: english
33 results on '"Lampiris H"'

Search Results

4. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

5. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy

6. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

7. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.

9. Association between household exposure and cycle threshold in COVID-19 infected health care workers.

10. Cycle Threshold to Test Positivity in COVID-19 for Return to Work Clearance in Health Care Workers.

11. Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool.

12. Opportunistic coinfection with Pneumocystis jirovecii and Coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia.

14. HIV latency in isolated patient CD4 + T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing.

17. Geriatric Syndromes in Older HIV-Infected Adults.

18. The Montreal Cognitive Assessment: A Pilot Study of a Brief Screening Tool for Mild and Moderate Cognitive Impairment in HIV-Positive Veterans.

19. Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.

20. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

21. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

22. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

23. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

24. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.

25. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.

26. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

27. Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual.

28. Covering all the bases: targeting HIV-1 integrase.

29. The independent effect of drug resistance on T cell activation in HIV infection.

30. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

31. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

32. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.

33. Streptococcus pneumoniae transmission in chronic-care facilities: description of an outbreak and review of management strategies.

Catalog

Books, media, physical & digital resources